New data indicate that its cell therapy could soon find a larger market.
Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.
These biotech stocks have just launched their first products.